Preston Klassen, SVP, Head Global Development at Orexigen Therapeutics, Inc. (OREX), sold 28,771 shares at $7.21 ($207K) on 2013-05-28, disclosed to the SEC on 2013-05-30.
Scheduled sale ($207k) by SVP, Head Global Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| MTCR | SELL | 2023-01-27 | $312K | — | Filing → |
| MTCR | SELL | 2022-04-20 | $22K | — | Filing → |
| MTCR | BUY | 2021-05-20 | $150K | — | Filing → |